Epithelioid sarcoma

From HemOnc.org - A Hematology Oncology Wiki

Revision as of 02:23, 29 January 2020 by Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")

(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Jump to navigation Jump to search

Section editor
	Elizabeth J. Davis, MD Vanderbilt University Nashville, TN ejdavis25

1 regimens on this page 1 variants on this page

All lines of therapy

Tazemetostat monotherapy

back to top

Regimen

FDA-recommended dose

Study	Evidence
See note	Phase II (RT)

Note: this study has not yet been published, to our knowledge.

Chemotherapy

Tazemetostat (Tazverik) 800 mg PO twice per day

Continued indefinitely

References

EZH-202: CT.gov

Retrieved from "https://hemonc.org/w/index.php?title=Epithelioid_sarcoma&oldid=42488"